NASDAQ:EVOK 4 November 2025

Evoke Pharma (EVOK) Stock Skyrockets on Buyout News – What’s Behind the Surge?

Evoke Pharma shares jumped about 135% to $10.77 on Nov. 4, 2025, after announcing a buyout by QOL Medical for $11 per share in cash. The $17 million deal, approved by both boards, is expected to close by year-end. Evoke’s only product is Gimoti, an FDA-approved nasal spray for diabetic gastroparesis. Q2 net sales rose 47% to $3.8 million, but the company remains unprofitable.

4 November 2025

Mergers & Acquisitions·NASDAQ:EVOK·Stock Market

Abbott Laboratories Valuation Faces Scrutiny Amid Recent Share Price Volatility
March 22, 2026, 10:19 AM EDT. Abbott Laboratories (ABT) has experienced recent share price weakness, sparking a reassessment of its valuation. Trading at $105.46, the stock shows a 6.02% gain over 30 days but reflects mixed longer-term returns, with a 15.08% year-to-date rise against a modest 5-year total shareholder return of 5.34%. Simply Wall St's analysis estimates a fair value of $113.88, suggesting an approximate 36% intrinsic discount and potential undervaluation. Despite a P/E ratio of 28.3x above the US Medical Equipment industry average, Abbott's strong fundamentals, innovation focus, and diversified portfolio support its position as a growth stock with defensive traits. However, risks include regulatory challenges and margin pressure from costs and competition. Investors should balance these rewards and risks to inform their investment outlook on ABT.